Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters
This large-scale prospective evidence demonstrates that adding AI-based plaque quantification to CCTA can materially change patient management, with potential to reduce adverse cardiac events. These results highlight the growing role of imaging AI in personalizing cardiovascular care.
Source
Cardiovascular Business
Related News
•AuntMinnie
GPT-4o AI Matches Radiologists in Follow-Up Imaging Recommendations
GPT-4o matched the performance of experienced radiologists and surpassed residents in recommending follow-up imaging from routine radiology reports.
•Cardiovascular Business
AI Leverages Head CTs for Automated Heart Risk Assessments
AI models can turn routine head CT scans into automated cardiovascular risk assessments, expanding the utility of radiology studies.
•Radiology Business
MRI AI for Parkinsonian Syndrome Gains FDA De Novo Clearance
Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.